DLT

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on: 
Monday, November 6, 2023
VISTA, Patient, MCP1, Biomarker, Pembrolizumab, IL-6, SITC, Immunotherapy, Date, Immunoglobulin G, Clinical trial, NK, DLT, Cytokine release syndrome, Radiation, Annual general meeting, Date-time group, Tumor microenvironment, CXCL10, Safety, CRS, Cancer, Society, Pharmaceutical industry, Vaccine, Kineta

SEATTLE, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the presentation of new positive data from its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, in patients with advanced solid tumors at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, presented the company’s poster unveiling the new clinical data.

Key Points: 
  • Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, presented the company’s poster unveiling the new clinical data.
  • VISTA blocking immunotherapy KVA12123 has performed remarkably well in demonstrating excellent safety and tolerability in the clinic.
  • KVA12123 achieved a greater than 90% VISTA RO at the 30 mg dose indicating that KVA12123 may be approaching an optimal clinical dose.
  • Additional monotherapy safety and efficacy data and combination therapy clinical data are anticipated in the second quarter of 2024.

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Patient, Cyclophosphamide, Infrared spectroscopy correlation table, Graft-versus-host disease, CD19, CD22, CDMO, Society, Neurotoxicity, ASH, Alemtuzumab, Hematology, Euronext Growth, San Diego Convention Center, Clinical trial, Cytokine release syndrome, Relapse, DLT, Allotransplantation, B-ALL, NHL, CRS, FCA, Investigational New Drug, Pharmaceutical industry, Medical device, Cosmetics, Vaccine

Cytokine release syndrome (CRS) Grade 1 or 2 occurred in all patients, and all CRS resolved with treatment.

Key Points: 
  • Cytokine release syndrome (CRS) Grade 1 or 2 occurred in all patients, and all CRS resolved with treatment.
  • No immune effector cell associated neurotoxicity (ICANS) or graft versus host disease (GvHD) was observed.
  • There were no UCART20x22 dose limiting toxicities (DLTs), and there was 1 DLT in connection with CLLS52 (alemtuzumab).
  • The study continues to enroll patients at dose level 2i (2.5 million cells/kg) with UCART22 P2.

Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023

Retrieved on: 
Thursday, November 2, 2023
Trae tha Truth, ECOG, Vomiting, CYP3A4, WT, Abstract, NPM1, KMT2A, OBD, PK, DLT, TKD, Cancer, Diabetes, ORR, Clinical study design, Safety, Patient, Cohort, HSCT, SETBP1, CR, DSM-IV codes, NUP214, DOR, Dicarboxylic acid, CRi, ASH, CD135, QT interval, RFS, FLT3, Arm, Cellular, FMS, Transplant, ALL, Toxic leukoencephalopathy, Gene family, Survival, Postcholecystectomy syndrome, DS, Trial of the century, Incidence, CRC, Infrared spectroscopy correlation table, AL, Osteopathic medicine in Canada, MN1, BID, CNS, KRAS, ATD, NUP98, Society, WBC, Pharmacokinetics, CLL, Acute leukemia, Common, ITD, Toxicity, AML, Cardiovascular disease, Pharmaceutical industry, Dentistry, Vaccine, Decitabine, DLBCL

Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.

Key Points: 
  • Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.
  • Methods: Doses of BMF-219 are escalated independently for each indication, initially in single-subject cohorts followed by a “3 + 3” design.
  • A subsequent amendment introduced quotas for KMT2Ar (MLL1r), NPM1 and other known menin-dependent mutations: CEBP/A, MLL1-PTD, MN1, NUP98, NUP214, PICALM-AF10, SETBP1.
  • The study was initiated in July 2023 and will enroll ~110 participants at approximately 30 sites.

Immutep Quarterly Activities Report Q1 FY24

Retrieved on: 
Tuesday, October 31, 2023
Immutep, ESMO, TPS, PFS, IDMC, HNSCC, Phase, DLT, Safety, Patient, Toxicity, Toxic leukoencephalopathy, Pharmaceutical industry

SYDNEY, AUSTRALIA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for the quarter ended 30 September 2023 (Q1 FY24).

Key Points: 
  • Immutep continued to prudently manage its cashflow over the first quarter of the new financial year (Q1 FY24), while strategically investing into clinical trial programs for efti.
  • Cash receipts from customers in Q1 FY24 were $132k, compared to $16k in Q4 FY23.
  • Total net cash outflows used in operating activities in the quarter was $12.86 million compared to $8.35 million in Q4 FY23.
  • Payment for the acquisition of Intellectual Property was $328k in Q1 FY24, compared to nil in Q4 FY23.

ADGM introduces the world's first DLT Foundations Regime

Retrieved on: 
Thursday, November 2, 2023
Register, Dame Alice Owen's School, Heart, Distributed ledger technology law, ABU, Distributed ledger, National Database and Registration Authority, RA, DLT, Cryptocurrency, Blockchain

This new regime comes in line with ADGM's strategy to foster initiatives in the broader blockchain and digital asset realm.

Key Points: 
  • This new regime comes in line with ADGM's strategy to foster initiatives in the broader blockchain and digital asset realm.
  • By harnessing the potential of technology, ADGM's DLT Foundations Regime offers an effective means to organise and promote governance whilst recognising the industry's need for decentralisation.
  • The introduction of the DLT Foundations Regime marks a revolutionary step forward, reinforcing ADGM's commitment to a proactive approach rooted in extensive cross-industry dialogue and collaboration with various stakeholders.
  • To view the full details of the Distributed Ledger Technology (DLT) Foundations Regulations 2023, please click HERE

ADGM introduces the world's first DLT Foundations Regime

Retrieved on: 
Thursday, November 2, 2023
Register, Dame Alice Owen's School, Heart, Distributed ledger technology law, ABU, Distributed ledger, National Database and Registration Authority, RA, DLT, Cryptocurrency, Blockchain

This new regime comes in line with ADGM's strategy to foster initiatives in the broader blockchain and digital asset realm.

Key Points: 
  • This new regime comes in line with ADGM's strategy to foster initiatives in the broader blockchain and digital asset realm.
  • By harnessing the potential of technology, ADGM's DLT Foundations Regime offers an effective means to organise and promote governance whilst recognising the industry's need for decentralisation.
  • The introduction of the DLT Foundations Regime marks a revolutionary step forward, reinforcing ADGM's commitment to a proactive approach rooted in extensive cross-industry dialogue and collaboration with various stakeholders.
  • To view the full details of the Distributed Ledger Technology (DLT) Foundations Regulations 2023, please click HERE

Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
CR, CRP, Acute myeloid leukemia, Food, Trae Waynes, Thrombocytopenia, Decitabine, Febrile neutropenia, Safety, CRH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Phenotype, Maintenance, Poster, Society, IDMC, ASH, DLT, Abstract, MRD, QT interval, ORR, SNDX, SAVE, NDA, Acute leukemia, Cellular, Transplant, ALL, AML, Neutropenia, Phase 1, HSCT, Pharmaceutical industry, Dentistry, Patient

WALTHAM, Mass., Nov. 2, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that updated data from multiple trials across its clinical program for revumenib, the Company's highly selective, oral menin inhibitor, will be featured in three poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023, in San Diego, California. Copies of the abstracts are now available online via the ASH website at www.hematology.org.

Key Points: 
  • The Company previously announced positive topline data from the protocol-defined pooled analysis of the pivotal Phase 2 portion of the AUGMENT-101 trial.
  • Based on the Independent Data Monitoring Committee (IDMC) recommendation, the Company stopped the trial to further accrual in the KMT2Ar cohorts.
  • Full data from the pivotal portion of the study will be reported at the meeting.
  • Title: Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study
    Session Name: 616.

SIX collaborates with the Swiss National Bank to pilot wholesale CBDC issuance in Switzerland

Retrieved on: 
Thursday, November 2, 2023
Central securities depository, SNB, Basler Kantonalbank, ICSD, CSD, Distributed ledger, Banque cantonale vaudoise, CBDC, DLT, UBS, SDX, Commerzbank, SIX, Interbank, Swiss National Bank, Cryptocurrency

SIX , the Swiss National Bank (SNB) and six commercial banks, will collaborate on a ground-breaking pilot focused on tokenized central bank money for financial institutions (wholesale CBDC).

Key Points: 
  • SIX , the Swiss National Bank (SNB) and six commercial banks, will collaborate on a ground-breaking pilot focused on tokenized central bank money for financial institutions (wholesale CBDC).
  • This pilot, Helvetia Phase III, will, for the first time, see the orchestration of a real Swiss Franc wCBDC settling digital securities transactions.
  • The pilot builds on the findings of earlier Helvetia Phases I and II by the BIS Innovation Hub, the SNB and SIX.
  • Participating banks will be able to issue digital Swiss Franc bonds, which will be settled against wCBDC on a delivery-versus-payment basis.

Euroclear delivers robust performance in Q3 2023

Retrieved on: 
Thursday, October 26, 2023
Well, Digital, KPI-driven code analysis, Sustainability, Finland, Korea Securities Depository, ESG, KTBS-TV, European Commission, Policy, European Central Bank, DNN, CSD, Workplace, PwC, Depository Trust & Clearing Corporation, Research, Investment, Capital Requirements Regulation 2013, Nature, Civil service commission, Environment, Growth, Sustainability reporting, Novo Holdings A/S, Sustainable finance, Sustainability Accounting Standards Board, Risk, DLT, Ecosystem, Clearstream, ETF, EUR, Annual, Corporate sustainability, World Bank, GRI, DTCC, World Economic Forum, Cryptocurrency, Security (finance), Renewable energy, Bank, Euroclear

Building on key advancements in making Korean Treasury bonds (KTBs) accessible through Euroclear Bank, the link will allow international investors efficient post-trade access to KTBs.

Key Points: 
  • Building on key advancements in making Korean Treasury bonds (KTBs) accessible through Euroclear Bank, the link will allow international investors efficient post-trade access to KTBs.
  • At the end of September 2023, Euroclear Bank's balance sheet had increased by EUR 45 billion year-on-year to a total of EUR 164 billion.
  • Euroclear Bank and Euroclear Investments are the two group issuing entities.
  • The summary income statements and financial positions at Q3 2023 for both entities are shown below.

Sygnum, Float & Fasanara join forces to tokenise private debt markets

Retrieved on: 
Thursday, October 26, 2023
Fintech, SME, Face, RBL, Entrepreneurship, Polygon, DLT, Partnership, USD, Citigroup, Software as a service, Bank, Cryptocurrency, Security (finance), Float

Exclusively available to Sygnum clients, it provides a unique opportunity to invest into a private debt portfolio alongside Fasanara Capital, a leading institutional fintech credit fund manager.

Key Points: 
  • Exclusively available to Sygnum clients, it provides a unique opportunity to invest into a private debt portfolio alongside Fasanara Capital, a leading institutional fintech credit fund manager.
  • The issuance of the Float token – the first private debt asset token – required the close collaboration of experts in lending, debt financing and tokenisation to make it a reality.
  • Through Sygnum, investors were able to get trusted exposure to asset classes previously seen as hard to access, like private debt markets, in a direct, fully compliant and fractional manner.
  • *Citi Report March 2023: Money, Token and Games **The Float Token originator is Float Finance AB (Sweden), which adheres to MiFID (or equivalent) requirements.